Cogent Biosciences, Inc. - Common Stock (COGT)
34.14
-1.19 (-3.37%)
NASDAQ · Last Trade: Mar 13th, 2:36 PM EDT
Detailed Quote
| Previous Close | 35.33 |
|---|---|
| Open | 35.68 |
| Bid | 34.06 |
| Ask | 34.15 |
| Day's Range | 33.91 - 37.10 |
| 52 Week Range | 3.720 - 43.73 |
| Volume | 850,258 |
| Market Cap | 2.92B |
| PE Ratio (TTM) | -20.94 |
| EPS (TTM) | -1.6 |
| Dividend & Yield | N/A (N/A) |
| 1 Month Average Volume | 1,774,772 |
Chart
About Cogent Biosciences, Inc. - Common Stock (COGT)
Cogent Biosciences Inc. is a biotechnology company focused on developing innovative therapies for genetically defined diseases. The company leverages its expertise in targeted drug development to create treatments that address the underlying genetic causes of various conditions, with a particular emphasis on rare diseases and severe forms of cancer. By utilizing advanced technologies and scientific research, Cogent aims to bring more effective therapeutic options to patients who are often underserved by existing treatments, advancing the field of precision medicine. Read More
News & Press Releases

Vera Therapeutics develops biologic therapies for serious immunological diseases, with a pipeline targeting high-burden conditions.
Via The Motley Fool · March 13, 2026

Celcuity develops targeted cancer therapies and diagnostics, leveraging proprietary technology to advance precision oncology solutions.
Via The Motley Fool · March 13, 2026

Praxis Precision Medicines develops therapies for central nervous system disorders, targeting unmet needs in neurology and psychiatry.
Via The Motley Fool · March 13, 2026

This biotech specializes in precision therapies for rare genetic diseases, with a pipeline targeting oncology and hematology indications.
Via The Motley Fool · March 13, 2026
As the first quarter of 2026 passes its midway point, a seismic shift in market leadership is unfolding on Wall Street. After years of playing second fiddle to the "Magnificent Seven" and the artificial intelligence arms race, small-cap stocks are finally having their moment in the sun. In a stunning
Via MarketMinute · March 12, 2026

This biotech firm develops precision therapies targeting rare genetic diseases, with a lead candidate focused on oncology indications.
Via The Motley Fool · February 17, 2026

Cogent Biosciences develops precision therapies for genetically defined diseases, with a pipeline targeting rare oncological conditions.
Via The Motley Fool · February 17, 2026
A large biotech fund that's an insider at Cogent Biosciences recently sold millions of shares amid the company's best annual performance ever in 2025.
Via The Motley Fool · February 1, 2026
Focused on precision therapies for rare diseases, this biotech firm reported a significant insider sale amid a year of sharp share gains.
Via The Motley Fool · January 11, 2026
What's going on in today's after hours sessionchartmill.com
Via Chartmill · December 30, 2025
A late-stage biotech with three pivotal trials underway just landed a major hedge-fund backer — here’s why the timing matters.
Via The Motley Fool · December 9, 2025
Amylyx Stock is up a staggering 166% over the past year, and this biotech-focused hedge fund is still doubling down.
Via The Motley Fool · December 9, 2025
A biotech specialist doubled down on Dyne ahead of a clinical readout that drew up investor fanfare — and the timing may be the entire story.
Via The Motley Fool · December 9, 2025
One investor is making a bold bet on Amylyx just as its 2026 catalyst calendar starts to take shape.
Via The Motley Fool · December 3, 2025
This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.
Via The Motley Fool · December 3, 2025
One fast-rising biotech just landed a heavyweight backer ahead of a pivotal presentation—here’s what investors should watch.
Via The Motley Fool · December 3, 2025
Relay’s comeback is gaining momentum—does this latest move signal rising conviction in its pipeline?
Via The Motley Fool · December 3, 2025
A science-first biotech fund just sized up its stake in an ALS-focused company heading into a pivotal year for the firm.
Via The Motley Fool · November 17, 2025
This biotech-focused fund made a big bet on Liquidia just as the company's YUTREPIA drug notched its first full quarter of commercialization.
Via The Motley Fool · November 17, 2025
A science-first biotech fund is leaning deeper into one company just as its lead program delivers some compelling early neuro data.
Via The Motley Fool · November 17, 2025
One biotech-focused investment firm cashed out of its stake in this drug developer as the stock soared—but seemingly missed out on a massive premium by mere weeks.
Via The Motley Fool · November 17, 2025
Keep an eye on the top gainers and losers in Monday's session, as they reflect the most notable price movements.
Via Chartmill · November 10, 2025
Curious to know what's happening on the US markets in the middle of the day on Monday? Join us as we explore the top gainers and losers in today's session.
Via Chartmill · November 10, 2025
Via Benzinga · November 10, 2025